Prevalence of Extended-spectrum ß-lactamase-producing Escherichia coli (ESBL E. coli) Among ICU Personnel's Stool Specimens in Teaching Hospitals in Tehran

Document Type : Brief Report

Authors

1 Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Infectious Diseases, Faculty of Medicine, Islamic Azad University, Tehran, Iran

3 Infectious Diseases and Tropical Medicine Research Center (IDTMC), School of Aerospace and Subaquatic Medicine, AJA University of Medical Sciences, Tehran, Iran

4 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, HD1 3DH, UK

5 College of Pharmacy, RAK Medical & Health Sciences University, Ras Al-Khaimah, United Arab Emirates

6 Department of Research and Development, DarooSazan Sorena Exir Pharmaceutical Company, Shiraz, Iran

10.30476/tips.2025.105123.1275

Abstract

Infections among intensive care unit (ICU) staff can lead to significant challenges, making their prevention crucial for improving patient outcomes and reducing healthcare costs. This study aimed to assess the presence of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL E. coli) in fecal samples from personnel working in the ICU of Besat Hospital and hospitals affiliated with the Islamic Azad University of Tehran. This descriptive study involved 64 ICU staff members from Besat Hospital and affiliated institutions, selected based on specific inclusion and exclusion criteria. The fecal samples were cultured to test for ESBL E. coli across four different stages. The average age of the participants was 37.08 years, with 64.1% were female. Among the ICU staff, 70.3% were nurses. About two-third (70.3%) of participants had ten or more years of work experience. The results showed that 37.5% tested positive for E. coli, with 20.3% specifically identified as ESBL E. coli. Our findings indicated that fecal samples of about one in five ICU personnel was positive for ESBL E. coli. Additionally, the risk of infection appears to be higher among older individuals, those with longer work experience, and nurses compared to other staff.

Highlights

Azar Bagheri-Alamooti (Google Scholar)
Moein Masjedi (Google Scholar)

Keywords

References

1.    Jalde SS, Choi HK. Recent advances in the development of β-lactamase inhibitors. J Microbiol. 2020 Aug;58(8):633-647. doi: 10.1007/s12275-020-0285-z. Epub 2020 Jul 27. PMID: 32720096.
2.    Jeong SH, Song W, Park MJ, Kim JS, Kim HS, Bae IK, et al. Boronic acid disk tests for identification of extended-spectrum beta-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases. Int J Antimicrob Agents. 2008 May;31(5):467-71. doi: 10.1016/j.ijantimicag.2007.12.014. Epub 2008 Mar 11. PMID: 18337065.
3.    Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian J Med Microbiol. 2004 Apr-Jun;22(2):75-80. PMID: 17642700.
4.    Hadziyannis E, Tuohy M, Thomas L, Procop GW, Washington JA, Hall GS. Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates☆. Diagn Microbiol Infect Dis 2000;36(2):113-7.
5.    Akbari M, Amir Mozaffari N, Peeri Dogaheh H. Prevalence of extended-spectrum beta lactamase in Entrobacteriaceae isolated from urinary tract infections in Ardabil, Iran. J Ardabil Uni Med Sci. 2014;14(3):285-91.
6.    Loyola S, Gutierrez LR, Horna G, Petersen K, Agapito J, Osada J, et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in cell phones of health care workers from Peruvian pediatric and neonatal intensive care units. Am J Infect Control. 2016 Aug 1;44(8):910-6. doi: 10.1016/j.ajic.2016.02.020. Epub 2016 Apr 7. PMID: 27067520; PMCID: PMC5253370.
7.    Abdel Rahman AT, Hafez SF, Abdelhakam SM, Ali-Eldin ZA, Esmat IM, Elsayed MS, et al. Antimicrobial resistant bacteria among health care workers in intensive care units at Ain Shams University Hospitals. J Egypt Soc Parasitol. 2010 Apr;40(1):71-83. PMID: 20503587.
8.    Aghamohammad S, Badmasti F, Shirazi AS, Dabiri H, Solgi H, Sabeti S, et al. Considerable rate of putative virulent phylo-groups in fecal carriage of extended-spectrum β-lactamase producing Escherichia coli. Infect Genet Evol. 2019 Sep;73:184-9. doi: 10.1016/j.meegid.2019.04.035. Epub 2019 May 2. PMID: 31054921.
9.    Aghamohammad S, Nikbin VS, Badmasti F, Shahcheraghi F. High heterogeneity of fecal carriage extended-spectrum beta-lactamase-producing E. coli isolated from iranian community and clinical settings. BMC Infect Dis. 2022 Mar 31;22(1):318. doi: 10.1186/s12879-022-07304-7. PMID: 35361158; PMCID: PMC8973555.
10.    Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B. Prevalence of ESBL in Escherichia coli Isolates Among ICU Patients in a Tertiary Care Hospital. J Clin Diagn Res. 2016 Sep;10(9):DC19-DC22. doi: 10.7860/JCDR/2016/21260.8544. Epub 2016 Sep 1. PMID: 27790433; PMCID: PMC5071933.
11.    Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003 Nov;47(4):273-95. doi: 10.1016/s0163-4453(03)00096-3. PMID: 14556752.
12.    Barzegar S, Arzanlou M, Teimourpour A, Esmaelizad M, Yousefipour M, MohammadShahi J, et al. Prevalence of the integrons and ESBL genes in multidrug-resistant strains of Escherichia coli isolated from urinary tract infections, Ardabil, Iran. Iran J Med Microbiol. 2022;16(1):56-65.
13.    Yousefipour M, Rasoulinejad M, Hadadi A, Esmailpour N, Abdollahi A, Jafari S, et al. Bacteria Producing Extended Spectrum β-lactamases (ESBLs) in Hospitalized Patients: Prevalence, Antimicrobial Resistance Pattern and its Main Determinants. Iran J Pathol. 2019 Winter;14(1):61-67. doi: 10.30699/IJP.14.1.61. Epub 2018 Dec 27. PMID: 31531102; PMCID: PMC6708561.
14.    Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. J Clin Microbiol. 2021 Nov 18;59(12):e0021321. doi: 10.1128/JCM.00213-21. Epub 2021 Sep 22. PMID: 34550809; PMCID: PMC8601225.
15.    Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001 Mar;49(3):270-6. doi: 10.1046/j.1532-5415.2001.4930270.x. PMID: 11300237.
16.    Dasgupta S, Das S, Chawan NS, Hazra A. Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med. 2015 Jan;19(1):14-20. doi: 10.4103/0972-5229.148633. PMID: 25624645; PMCID: PMC4296405.
17.    Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis. 2016 Aug 1;63(3):310-8. doi: 10.1093/cid/ciw283. Epub 2016 May 3. Erratum in: Clin Infect Dis. 2016 Sep 15;63(6):851. doi: 10.1093/cid/ciw497. PMID: 27143671.
18.    Haller S, Eller C, Hermes J, Kaase M, Steglich M, Radonić A, et al. What caused the outbreak of ESBL-producing Klebsiella pneumoniae in a neonatal intensive care unit, Germany 2009 to 2012? Reconstructing transmission with epidemiological analysis and whole-genome sequencing. BMJ Open. 2015 May 11;5(5):e007397. doi: 10.1136/bmjopen-2014-007397. PMID: 25967999; PMCID: PMC4431171.
Trends in Pharmaceutical Sciences and Technologies
Volume 12, Issue 1
March 2026
Pages 1-8

Files

Share

How to cite

Statistics